Physician profile
Bernard Stein
NPI 1215019849
$5,501.59
in general payments reported to CMS, 2019-2025
31 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $396 · 2021: $716 · 2022: $769 · 2023: $749 · 2024: $1,060 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,840.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,602.23 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Janssen Biotech, INC. | $890.12 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.80 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $414.32 | 2019-2025 | Entyvio |
| Celgene Corporation | $286.12 | 2021-2023 | Zeposia |
| Pfizer INC. | $180.64 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $169.77 | 2024 | Voquezna |
| Genzyme Corporation | $139.78 | 2024-2025 | |
| Madrigal Pharmaceuticals | $125.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $124.89 | 2021-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $115.55 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $106.76 | 2021-2023 | Rebyota |
| Lilly USA, LLC | $105.60 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $100.23 | 2019-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $98.52 | 2022-2023 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $84.55 | 2022-2023 | Linzess |
| Allergan, INC. | $60.31 | 2019 | |
| Braintree Laboratories, INC. | $57.40 | 2021-2023 | Suflave |
| Ardelyx, INC. | $55.44 | 2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $49.02 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $41.05 | 2022-2023 | Dificid |
| Amgen INC. | $35.51 | 2020-2023 | Amjevita, Avsola |
| Axonics, INC. | $34.26 | 2024 | Axonics |
| Celltrion USA INC. | $28.84 | 2024 | Vegzelma |
| Gilead Sciences, INC. | $28.82 | 2021 | |
| Novo Nordisk INC | $24.83 | 2025 | Wegovy |
| Biocon Biologics INC | $24.61 | 2025 | Yesintek |
| Daiichi Sankyo INC. | $21.56 | 2019 | |
| Ucb, INC. | $18.83 | 2019 | |
| Shire North American Group INC | $14.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$46,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.